Barbara Leyman - 08 Jul 2025 Form 4 Insider Report for SUTRO BIOPHARMA, INC. (STRO)

Role
Chief Business Officer
Signature
/s/ David Pauling as attorney-in-fact for Barbara Leyman
Issuer symbol
STRO
Transactions as of
08 Jul 2025
Net transactions value
-$6,976
Form type
4
Filing time
26 Aug 2025, 21:21:26 UTC
Previous filing
08 Apr 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Leyman Barbara Chief Business Officer C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO /s/ David Pauling as attorney-in-fact for Barbara Leyman 26 Aug 2025 0002028309

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STRO Common Stock Options Exercise $0 +25,000 $0.000000 25,000 08 Jul 2025 Direct
transaction STRO Common Stock Tax liability $6,976 -8,944 -36% $0.7800 16,056 08 Jul 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STRO Restricted Stock Units (RSUs) Options Exercise $0 -25,000 -25% $0.000000 75,000 08 Jul 2025 Common Stock 25,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.
F2 Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
F3 The RSUs vest as to 1/4th of the total award annually beginning on July 8, 2025, subject to the reporting person's continued service to the Issuer through each vesting date.